Biocon’s launch of the world’s first bio-similar of Trastuzumab, a critical breast cancer drug, is unlikely to benefit patients in a big way if the company sticks to the prices it has indicated, cl
Links:
[1] http://admin.indiaenvironmentportal.org.in/news/biocon-breast-cancer-drug-too-expensive-say-health-activists
[2] http://admin.indiaenvironmentportal.org.in/category/newspaper/economic-times-new-delhi
[3] http://admin.indiaenvironmentportal.org.in/category/thesaurus/cancer
[4] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[5] http://admin.indiaenvironmentportal.org.in/category/thesaurus/breast
[6] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drug-industry